NIAID’s Transmission-Blocking Malaria Vaccine

Dept. of Health and Human Services

Laboratory: National Institute of Allergy and Infectious Diseases (NIAID)

Technology: Transmission-blocking malaria vaccine

Opportunity: NIAID is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate or commercialize malaria vaccines, diagnostics and therapeutics.

Details: There is no vaccine for malaria, and there is growing resistance to existing anti-malarial drugs. Sexual stage-specific antigens are of interest as vaccine candidates because disruption of these antigens would reduce the parasite’s fertility and, thus, its infectivity.

This invention claims methods and compositions for delivering a Plasmodium P47 vaccine or antibody to P47 to prevent Plasmodium falciparum or Plasmodium vivax malaria. P47 and other antigens have been mentioned as potential transmission-blocking vaccines due to their surface location on gametes. The gene for P47 antigens is also well-characterized. Recent discoveries have noted that P47 allows the parasite to suppress or evade the immune system, thereby ensuring the mosquitoes' survival. Recent discoveries have also shown the mechanism by which P47 enables survival of the parasite by manipulation of the mosquito immune system. Based on the critical role of P47 antigens in transmission, disrupting the function of P47 by various means can provide an innovative and forceful means to control and/or reduce the prevalence of malaria. 


  • Single protein malaria transmission-blocking vaccine
  • Cost-effective, simple manufacturing process for vaccine
  • Potentially lower-cost malarial vaccine for developing/developed countries

Applications: This novel NIAID invention has potential application as a malaria vaccine, diagnostic, and therapeutic.

Contact: For more information on collaborative opportunities for this invention, contact Tristan J. Mahyera at

To view the original NIH available technology posting, visit